






Implementation Challenges of Apprequested HIV and STI Home Test Kits among Men Who Have Sex with Men

RYAN ZAHN, SABINA HIRSHFIELD, GORDON MANSERGH, ROB STEPHENSON, PATRICK SULLIVAN

2019 HIV DIAGNOSTICS CONFERENCE ATLANTA, GA MARCH 27, 2019



Background

- Men who have sex with men (MSM): disproportionately impacted by HIV in the United States
- Testing rates remain suboptimal; prevention services underutilized
- Home-based HIV and STI testing is feasible and acceptable
- Mobile apps offer the opportunity to provide services at scale, and in areas not fully served by conventional prevention providers



Study Overview & Mobile App



M-Cubed Study: Mobile Messaging for Men

Objective: Evaluate the use and effectiveness of a mobile app with tailored prevention messages in supporting sexual health of MSM.

Study Design: Randomized Controlled Trial

- Participants download and use app for 3-months
- Control participants are offered the app at the 9-month visit
- Surveys completed at baseline, 3-, 6-, and 9-months

1200+ MSM in Atlanta, GA; New York City, NY; Detroit, MI.



Eligibility and Participant Recruitment

Eligibility Criteria

- MSM in Atlanta, Detroit, or New York City MSAs
- Aged 18+ years
- Sexually active with men (past year)
- Is included in one of the following risk groups
 - HIV seropositive
 - HIV seronegative at "lower risk"
 - HIV seronegative at "higher risk"

Recruitment Goals

- Evenly split by city
- Evenly split by risk group within each city
- At least 30% non-white

Multiple Recruitment Methods


- Venue- and event-based
- Online advertisements
- Social Media
- Print advertisements
- Referrals
- Community outreach
- Public transportation




App Features Encourage Testing

- "Quizzes"
 - Behavioral risk assessment
 - PrEP indication
 - PEP indication
 - Testing frequency
 - HIV treatment
- Test planner
- PrEP and ART medical provider locators
- HIV and STI testing site locators
- Insurance information
- MOBILE MESSAGING

- Free Commodity Ordering
 - Condoms and lubricant
 - HIV test kits (Oraquick)
 - STI CareKits
- Risk-tailored brief prevention messages





App Messages

Messages pushed out to participants over a 3-month intervention

Written (1-2 sentences; sent approx. every 2 days): 36 core messages to everyone with 9 additional messages targeted by HIV-status/risk

Video (~1 minute, 1 sent per week): 12 core video messages to everyone that reinforce written messages/domains





STI CareKits



STI CareKits

- Home-based specimen collection kits for STI testing
 - Urine (gonorrhea/chlamydia)
 - Throat swab (gonorrhea/chlamydia)
 - Rectal swab (gonorrhea/chlamydia)
 - Blood microvette (syphilis)
- Written instructions and video demonstrations
- Specimens returned to Emory CfAR lab
- No follow-up from staff until return of results





STI Testing Process

Order fulfillment

Participants order items through app or emailed link

Information submitted to Amazon fulfillment

Shipment tracking and participant communication

Specimen testing

Participants register kits at unique URLs

Specimens collected using CareKit instructions

Specimens shipped to lab(s) in prepaid mailing envelopes

Results returned

Lab results linked to box ID number

Data processing to link results to participants

Studies contact participants with results


Results




Participant characteristics

Characteristics	Overall	Atlanta	Detroit	New York City						
Total Enrolled	1229	478 (39%)	335 (27%)	416 (34%)						
Total Intervention Participants	611	239 (39%)	166 (27%)	206 (34%)						
Intervention Participants Only										
Risk Group HIV Neg, Lower Risk HIV Neg, Higher Risk HIV Positive	202 (33%) 215 (35%) 194 (32%)	71 (30%) 71 (30%) 97 (40%)	60 (36%) 78 (47%) 28 (17%)	71 (34%) 66 (32%) 69 (33%)						
Age (Median/Range)	32	36 (19-71)	28 (18-70)	32 (19-75)						
Race American Indian/Alaska Native Asian Black or African American White Mixed Race Other Don't Know	1 (<1%) 28 (5%) 213 (35%) 286 (47%) 43 (7%) 39 (6%) 1 (<1%)	1 (<1%) 6 (3%) 100 (42%) 106 (44%) 19 (8%) 7 (3%) 0 (0%)	0 (0%) 9 (5%) 39 (23%) 100 (60%) 11 (7%) 7 (4%) 0 (0%)	0 (0%) 13 (6%) 74 (36%) 80 (39%) 13 (6%) 25 (12%) 1 (<1%)						


HIV and STI Kit Orders by Study Site



HIV and STI Kit Orders by Risk Group



STI Specimen Return



Challenges

- Requiring kit registration presents linkage barrier
- Users need encouragement to complete collection
- Lack of syphilis samples may indicate user difficult
- The study does not receive HIV test results

Next Steps

- Continuous process improvements
 - Active reminders/follow-up by study staff
 - Instruction material edits
 - Optimizing linkage of test results
 - Examining fulfillment and business processes
- Waitlist-control to begin app usage
- In-depth interviews to understand home test kit usage
- Study end in September 2019



Summary

- Ordering of home-based test kits for HIV and STIs was high among users of a mobile app
- Proper kit registration and return was low
 - Need for improved linkage of results
 - May require assistance and reminders
- Return of blood sample was particularly low
 - May indicate difficultly in collecting the sample
 - Other options for syphilis testing should be explored



Acknowledgements

Emory University

Patrick Sullivan (PI)
Sarah Wiatrek, Ruth Dana, Marc Padilla
Aaron Siegler, Eli Rosenberg

University of Michigan

Rob Stephenson (co-I) Erin Rogers, Ana Alas

SUNY Downstate & Public Health Solutions

Sabina Hirshfield (co-I)
Irene Yoon, Steven Houang
Martin Downing, Mary Ann Chiasson

CDC Division of HIV/AIDS Prevention

Gordon Mansergh (PO) Heather Saul, Evelyn Olansky (ICF) Deb Gelaude

Consultants

Jose Bauermeister, University of Pennsylvania Keith Horvath, University of Minnesota

Laboratories

Emory University Center for AIDS Research Centers for Disease Control and Prevention

All of the fantastic participants of the M-Cubed Study

Thank you!

STI Testing

		Study site			HIV Risk group		
Vit and Specimen	Overall (N= 611)	Atlanta (n= 239)	Michigan (n= 166)	NYC	Negative Lower-risk (n= 202)	Negative Higher-risk (n=215)	Positive (n=194)
Kit and Specimen Kits Ordered	n(%)	(11- 239)	(11– 100)	(n= 206)	(11- 202)	(11–215)	(11-194)
	222 (222()	22 (442()	0.4 (==0.4)	-c (c-c()	22 (122 ()	((·)
HIV Kit	265 (43%)	98 (41%)	91 (55%)	76 (37%)	98 (49%)	117 (54%)	50 (26%)
STI Kit	293 (48%)	114 (48%)	84 (51%)	95 (46%)	100 (50%)	117 (54%)	76 (39%)
Any STI Specimen Returned	56 (19%)	18 (16%)	20 (24%)	18 (19%)	22 (22%)	27 (23%)	7 (9%)
Urine samples returned	50 (17%)	15 (13%)	20 (24%)	15 (16%)	20 (20%)	25 (21%)	5 (7%)
Rectal swabs returned	52 (18%)	16 (14%)	19 (23%)	17 (18%)	21 (21%)	26 (22%)	5 (7%)
Pharyngeal swabs returned	52 (18%)	16 (14%)	19 (23%)	17 (18%)	21 (21%)	26 (22%)	5 (7%)
Blood sample returned	23 (8%)	10 (9%)	8 (10%)	5 (5%)	9 (9%)	11 (9%)	3 (4%)